Clinical Trial Update: Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib plus pemetrexed in advanced non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Henan Provincial People's Hospital | Conditions: Non-squamous Cell Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN